Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score As a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors

Overview

Journal Perm J

Specialties General Medicine
Health Services

Date 2015 Jul 16

PMID 26176568

Citations 8

Authors

Roger A Bitar

Affiliations

Soon will be listed here.

Abstract

Febrile neutropenic episodes in patients with solid tumors were identified electronically from 10/1/2008 to 11/15/2010. Inclusion criteria were met in 198 episodes. Sensitivity, specificity, and positive and negative predictive values of the MASCC risk index score vs complications were, respectively, 94%, 29.6%, 57.7%, and 82.9%. An MASCC risk index score of 21 or greater could not be used as a criterion for "no complication/ do not admit." Inability to eat should be an admission criterion.

Citing Articles

Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.

Hwang S, Kwon K, Kim Y, Bae S, Chang H, Kim S Sci Rep. 2021; 11(1):9048.

PMID: 34526516 PMC: 8443648. DOI: 10.1038/s41598-021-88207-6.

Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.

Bhardwaj P, Emmich M, Knee A, Ali F, Walia R, Roychowdhury P Support Care Cancer. 2021; 29(10):5905-5914.

PMID: 33761002 PMC: 7987550. DOI: 10.1007/s00520-021-06154-4.

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.

Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L Cancer Biol Med. 2020; 17(4):896-909.

PMID: 33299642 PMC: 7721096. DOI: 10.20892/j.issn.2095-3941.2020.0069.

Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models.

Du X, Min J, Shah C, Bishnoi R, Hogan W, Lemas D Int J Med Inform. 2020; 139:104140.

PMID: 32325370 PMC: 7255942. DOI: 10.1016/j.ijmedinf.2020.104140.

Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia.

Baugh C, Faridi M, Mueller E, Camargo Jr C, Pallin D PLoS One. 2019; 14(5):e0216835.

PMID: 31120893 PMC: 6532959. DOI: 10.1371/journal.pone.0216835.

References

Flowers C, Seidenfeld J, Bow E, Karten C, Gleason C, Hawley D . Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31(6):794-810. DOI: 10.1200/JCO.2012.45.8661. View

Klastersky J, Paesmans M, Rubenstein E, Boyer M, Elting L, Feld R . The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16):3038-51. DOI: 10.1200/JCO.2000.18.16.3038. View

Bone R, Balk R, Cerra F, Dellinger R, Fein A, Knaus W . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101(6):1644-55. DOI: 10.1378/chest.101.6.1644. View

Hughes W, Pizzo P, Wade J, Armstrong D, Webb C, Young L . Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992; 15 Suppl 1:S206-15. DOI: 10.1093/clind/15.supplement_1.s206. View

Rubenstein E, Rolston K, Benjamin R, Loewy J, Escalante C, Manzullo E . Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993; 71(11):3640-6. DOI: 10.1002/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h. View

Escalante C, Weiser M, Manzullo E, Benjamin R, Rivera E, Lam T . Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer. 2004; 12(9):657-62. DOI: 10.1007/s00520-004-0613-6. View

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L . Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006; 24(25):4129-34. DOI: 10.1200/JCO.2005.03.9909. View

Elting L, Lu C, Escalante C, Giordano S, Trent J, Cooksley C . Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008; 26(4):606-11. DOI: 10.1200/JCO.2007.13.8222. View

10.

Innes H, Lim S, Hall A, Chan S, Bhalla N, Marshall E . Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2007; 16(5):485-91. DOI: 10.1007/s00520-007-0334-8. View

11.

Baskaran N, Gan G, Adeeba K . Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol. 2008; 87(7):563-9. DOI: 10.1007/s00277-008-0487-7. View

12.

Andre S, Taboulet P, Elie C, Milpied N, Nahon M, Kierzek G . Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care. 2010; 14(2):R68. PMC: 2887190. DOI: 10.1186/cc8972. View

13.

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

14.

Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M . Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?. Support Care Cancer. 2010; 19(7):1001-8. DOI: 10.1007/s00520-010-0925-7. View

15.

Ahn S, Lee Y, Chun Y, Kwon I, Kim W, Lim K . Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer. 2010; 19(8):1151-8. DOI: 10.1007/s00520-010-0928-4. View

16.

Carmona-Bayonas A, Gomez J, Gonzalez-Billalabeitia E, Canteras M, Navarrete A, Gonzalvez M . Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011; 105(5):612-7. PMC: 3188929. DOI: 10.1038/bjc.2011.284. View

17.

Hui E, Leung L, Poon T, Mo F, Chan V, Ma A . Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural.... Support Care Cancer. 2010; 19(10):1625-35. DOI: 10.1007/s00520-010-0993-8. View

18.

Uys A, Rapoport B, Anderson R . Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004; 12(8):555-60. DOI: 10.1007/s00520-004-0614-5. View

19.

Pompei P, Charlson M, Ales K, MacKenzie C, Norton M . Relating patient characteristics at the time of admission to outcomes of hospitalization. J Clin Epidemiol. 1991; 44(10):1063-9. DOI: 10.1016/0895-4356(91)90008-w. View